Highlights
In a harmonized individual-participant analysis of 14 prospective cohorts, higher serum interleukin-6 (IL-6) concentrations were associated with increased risk across all nine prespecified cardiovascular and mortality outcomes.
The strongest association was observed for coronary heart disease-specific mortality: adjusted hazard ratio 2.12 (95% CI: 1.88-2.39) for the highest versus lowest IL-6 quartile. Even the weakest association, for myocardial infarction, remained clinically meaningful at 1.45 (95% CI: 1.28-1.64).
Associations were consistent across chronic kidney disease, diabetes, body mass index categories, high-sensitivity C-reactive protein (hsCRP) strata, and secondary prevention populations, reinforcing IL-6 as a broad inflammatory risk signal rather than a marker limited to a single phenotype.
IL-6 provided modest incremental discrimination beyond hsCRP for stroke, heart failure, total cardiovascular disease, total coronary heart disease, and mortality outcomes, suggesting potential complementary value in risk stratification.
Background
Residual inflammatory risk has become a central concept in cardiovascular medicine. Even after intensive control of low-density lipoprotein cholesterol, blood pressure, diabetes, and smoking exposure, many patients continue to experience myocardial infarction, stroke, heart failure, and premature death. A growing body of translational and clinical evidence suggests that inflammatory signaling is not merely an epiphenomenon of vascular injury, but a biologically active driver of atherosclerosis, plaque destabilization, thrombosis, and myocardial remodeling.
Among inflammatory mediators, IL-6 occupies an especially important mechanistic position. It lies upstream of acute-phase reactants such as C-reactive protein and fibrinogen, participates in leukocyte recruitment, endothelial activation, and hepatic inflammatory responses, and has been linked to plaque progression and adverse cardiac remodeling. Interest in IL-6 intensified after randomized trials of anti-inflammatory strategies showed that targeting inflammation can reduce cardiovascular events, most notably with IL-1 beta inhibition in CANTOS, which indirectly reduced IL-6 signaling. More recently, direct IL-6 pathway inhibition has emerged as a plausible therapeutic strategy, but clinicians still need better epidemiologic context: how strongly does circulating IL-6 predict different cardiovascular outcomes, does this vary across diverse populations, and does it add information beyond hsCRP?
The Cross Cohort Collaboration addresses these questions using pooled individual-level data from multiple community-based cohorts. This design is particularly valuable because it improves statistical power, broadens representation, and allows harmonized subgroup analyses that single cohorts often cannot support.
Study Design
Overall design
This study was an individual-level pooled analysis of 14 prospective cohorts participating in the Cross Cohort Collaboration. Investigators harmonized baseline IL-6 measurements, clinical covariates, and outcome definitions to assess the relationship between serum IL-6 concentrations and future cardiovascular events and mortality.
Population
The analysis included 59,396 participants. Mean age was 63.6 ± 12.4 years, 67.6% were women, and 20.6% were Black. The median IL-6 concentration was 1.91 pg/mL. The use of multiple large cohorts improved ethnic and clinical diversity relative to many prior biomarker studies.
Exposure
The principal exposure was circulating serum IL-6 concentration measured at baseline. IL-6 was analyzed both categorically, by quartiles, and continuously after logarithmic transformation, an appropriate approach given the right-skewed distribution typically seen for inflammatory biomarkers.
Outcomes
Nine prespecified outcomes were evaluated: myocardial infarction, stroke, atrial fibrillation, heart failure, total coronary heart disease (CHD), total cardiovascular disease (CVD), all-cause mortality, CVD-specific mortality, and CHD-specific mortality. The longest median follow-up was 15.8 years for CVD-specific mortality, allowing assessment of long-term prognostic value.
Statistical approach
Multivariable-adjusted Cox proportional hazards models were used to estimate hazard ratios and 95% confidence intervals. The abstract indicates that analyses controlled for clinical covariates, although the exact covariate set is not detailed there. Prespecified subgroup analyses examined chronic kidney disease status, diabetes status, hsCRP concentrations, body mass index categories, and secondary prevention populations. Incremental discrimination was assessed using area under the curve comparisons across four models: a base model, base plus IL-6, base plus hsCRP, and base plus both biomarkers.
Key Results
IL-6 predicted all nine outcomes
The central finding is notable for its breadth: higher IL-6 concentrations were associated with increased risk for every outcome studied. This is important clinically because it suggests IL-6 is not only an atherosclerotic biomarker but also a marker of broader cardiovascular vulnerability, including stroke, heart failure, atrial fibrillation, and death.
The strongest association was for CHD-specific mortality. Participants in the highest IL-6 quartile had more than double the risk of CHD death compared with those in the lowest quartile, after multivariable adjustment: hazard ratio 2.12 (95% CI: 1.88-2.39). Such an effect size is substantial for an observational biomarker study, especially after adjustment for conventional risk factors.
The weakest association was seen for myocardial infarction, with an adjusted hazard ratio of 1.45 (95% CI: 1.28-1.64) for the highest versus lowest quartile. Even this lower estimate remains statistically robust and clinically relevant, particularly given the multifactorial nature of myocardial infarction risk.
Although the abstract does not provide hazard ratios for the remaining seven outcomes, it states clearly that all were positively associated with higher IL-6 concentrations. This uniformity across outcomes strengthens the biological plausibility of IL-6 as a systemic mediator of cardiovascular risk rather than a marker tied to one narrow disease pathway.
Consistency across clinically relevant subgroups
A particularly valuable aspect of the study is the stability of the associations across key subgroups. The predictive relationship between higher IL-6 and adverse outcomes remained robust in people with and without chronic kidney disease, with and without diabetes, across body mass index categories, and across hsCRP strata. The findings also extended to secondary prevention populations, indicating that IL-6 retains prognostic relevance in patients who already have established cardiovascular disease.
This consistency matters because inflammatory biomarkers can be difficult to interpret when they are strongly confounded by obesity, metabolic disease, kidney dysfunction, or baseline cardiovascular disease burden. The CCC analysis suggests that IL-6 captures risk information that remains relevant within each of these clinical contexts.
Incremental discrimination beyond hsCRP
hsCRP is the inflammatory biomarker most familiar to practicing clinicians. It is inexpensive, standardized, and supported by decades of epidemiologic and interventional literature. Therefore, a practical question is whether IL-6 offers any information beyond hsCRP.
In this study, IL-6 alone demonstrated modest additive discrimination beyond hsCRP for several outcomes: stroke, heart failure, total CVD, total CHD, and mortality. The wording is important. The improvement was modest rather than transformative, but it was consistent enough to suggest that IL-6 is not simply interchangeable with hsCRP. Mechanistically, that makes sense because IL-6 is upstream of hepatic CRP synthesis and may therefore better reflect the active inflammatory signaling axis itself.
From a clinical implementation perspective, however, modest gains in discrimination do not automatically justify routine testing. Whether IL-6 should enter everyday risk prediction will depend on assay availability, standardization, cost, reproducibility, calibration within risk models, and, most importantly, whether identifying elevated IL-6 changes treatment decisions or outcomes.
Clinical Interpretation
Why these findings matter now
This study arrives at a time when anti-inflammatory cardiology is moving from concept toward therapeutic precision. The field already recognizes that not all inflammation is equivalent. Some inflammatory pathways may be causal, others merely associative, and broad immunosuppression may cause more harm than benefit. IL-6 stands out because it is central to innate immune signaling and has already been implicated by human genetics, mechanistic studies, and post hoc analyses from anti-inflammatory trials.
The CCC results support the idea that IL-6-mediated inflammation is clinically meaningful across a wide spectrum of cardiovascular disease. The strength of association with fatal outcomes is especially striking. Biomarkers that predict mortality more strongly than nonfatal myocardial infarction often capture a broader pathobiologic burden, potentially including plaque instability, thrombogenicity, myocardial dysfunction, vascular inflammation, frailty, and competing systemic risk.
Potential implications for risk assessment
These data do not establish IL-6 as a routine clinical test, but they do elevate its credibility as a candidate biomarker for residual inflammatory risk. In selected settings, IL-6 could eventually help identify patients who appear adequately treated by traditional metrics yet remain at high inflammatory risk. That application may be especially relevant in secondary prevention, where clinicians frequently confront patients with recurrent events despite lipid lowering, blood pressure control, and antithrombotic therapy.
The modest improvement over hsCRP suggests IL-6 may be most useful not as a replacement, but as a complementary marker in research settings, enriched-risk trial populations, or future multimarker algorithms. Before widespread adoption, clinicians will need data on assay harmonization, biologic variability, threshold definition, and treatment-response monitoring.
Potential implications for therapeutics
The findings also provide epidemiologic support for therapeutic strategies that inhibit IL-6 signaling. That does not mean biomarker association alone proves treatment benefit. Observational analyses cannot determine whether lowering IL-6 will reduce all the outcomes with the same magnitude suggested here. But the consistency across outcomes and subgroups adds weight to the hypothesis that IL-6 is not just correlated with risk; it may sit within a causal pathway that is therapeutically actionable.
As IL-6-targeted therapies are explored in cardiovascular populations, this study helps define the populations in whom such therapies might be relevant: diverse community-dwelling adults, patients with common metabolic comorbidities, and individuals with established cardiovascular disease.
Strengths of the Study
The study has several major strengths. First, the sample size is large, with nearly 60,000 participants, allowing precise estimates and a wide range of subgroup analyses. Second, individual-level harmonization across 14 cohorts is methodologically stronger than aggregate meta-analysis because it enables more consistent modeling and endpoint definition. Third, the cohorts were multiethnic and included a substantial proportion of women and Black participants, improving representativeness relative to older biomarker studies that were predominantly White and male. Fourth, the range of outcomes was unusually broad, extending beyond traditional atherosclerotic endpoints to atrial fibrillation, heart failure, and cause-specific mortality.
Finally, the comparison with hsCRP is clinically pragmatic. Rather than merely showing that IL-6 is associated with events, the authors tested whether it adds information beyond the inflammatory biomarker most commonly used in cardiovascular medicine.
Limitations and Cautions
Several limitations should temper interpretation. Most importantly, this was an observational study. Even with multivariable adjustment, residual confounding remains possible. IL-6 can rise in response to chronic inflammatory diseases, occult infection, frailty, adiposity, and subclinical illness, all of which may contribute independently to adverse outcomes.
Second, the abstract does not describe repeated IL-6 measurements. A single baseline value may not fully represent long-term inflammatory exposure, and within-person variability may attenuate true associations or complicate clinical application.
Third, biomarker assay methods, specimen storage, and calibration may differ across cohorts despite harmonization efforts. This is a common challenge in pooled biomarker studies and may affect absolute thresholds more than relative associations.
Fourth, the reported improvement in discrimination was modest. This is not unusual for biomarkers added to already strong clinical models, but it means that statistical significance should not be confused with immediate bedside utility.
Fifth, cause-specific mortality analyses can be influenced by adjudication differences across cohorts. Even so, the consistency of the direction of effect argues against a purely artifactual finding.
How This Fits With Existing Evidence
The current analysis is aligned with a broader literature linking IL-6 pathway activity to cardiovascular events. In the CANTOS trial, reductions in inflammatory biomarkers including IL-6 were associated with lower recurrent event rates among post-myocardial infarction patients receiving canakinumab. Mendelian randomization studies have also suggested that genetically proxied downregulation of IL-6 signaling may reduce coronary disease risk. Together, these lines of evidence strengthen the argument that IL-6 may represent more than a nonspecific inflammatory bystander.
At the same time, this study adds something important that prior work often lacked: scale, diversity, and breadth of outcomes in community-based cohorts. It suggests that IL-6 may have prognostic relevance not only in highly selected secondary prevention populations, but across the continuum from primary prevention to established disease.
Practical Takeaways for Clinicians
For clinicians, the immediate message is not that IL-6 should be ordered routinely tomorrow. Rather, the main takeaway is conceptual and strategic. Inflammation, and specifically IL-6-mediated inflammation, appears to be a durable and broadly applicable cardiovascular risk axis. Patients with elevated inflammatory burden may remain vulnerable even when conventional risk factors are treated.
hsCRP remains the more practical inflammatory biomarker in routine care, given assay accessibility and greater familiarity. However, IL-6 may become increasingly relevant in specialized cardiovascular prevention clinics, translational studies, biomarker-enriched trials, and perhaps future precision-therapy frameworks if targeted anti-inflammatory treatments prove safe and effective.
Clinicians should also recognize that elevated IL-6 is not disease-specific. If testing is performed in a research or specialized context, interpretation should consider infections, autoimmune disease, kidney dysfunction, obesity, malignancy, and other systemic inflammatory states.
Conclusion
The Cross Cohort Collaboration provides strong epidemiologic evidence that higher serum IL-6 concentrations independently predict a wide range of cardiovascular events and death. In nearly 60,000 participants from 14 prospective cohorts, the association was consistent across nine outcomes, robust in important subgroups, and strongest for CHD-specific mortality. IL-6 also added modest discriminatory value beyond hsCRP for several major outcomes.
These findings reinforce IL-6 as a central marker of residual inflammatory risk and strengthen the rationale for continued investigation of IL-6 pathway inhibition in cardiovascular prevention. The next steps are not merely confirmatory biomarker studies, but translational work to determine which patients benefit most from inflammatory profiling, what IL-6 thresholds are clinically actionable, and whether directly lowering IL-6 signaling improves hard outcomes without unacceptable safety trade-offs.
Funding and ClinicalTrials.gov
Funding details were not provided in the abstract cited here. Readers should consult the full Journal of the American College of Cardiology publication for specific funding disclosures and author conflict-of-interest statements. ClinicalTrials.gov registration is not applicable because this was a pooled analysis of prospective cohorts rather than an interventional clinical trial.
References
1. Yao Z, Dardari ZA, LaMonte MJ, Matsushita K, Ballantyne CM, Lima JA, Vasan RS, Simonsick EM, Appel LJ, Cohen DL, Judd S, Cawthon PM, Shah AM, Weber BN, Cao T, Dzaye O, Tasdighi E, Jelwan Y, Jha KK, Psaty BM, Bis JC, Olson NC, Lash JP, Cushman M, Eaton CB, Blaha MJ. The Prognostic Value of Serum Interleukin-6 Concentrations for 9 Cardiovascular and Mortality Outcomes: The Cross Cohort Collaboration (CCC). Journal of the American College of Cardiology. 2026-05-27. PMID: 42201287.
2. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377:1119-1131.
3. Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream to Identify Novel Targets for Atheroprotection. Circ Res. 2016;118:145-156.
4. Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JEL, Shah T, Sofat R, Stender S, Johnson PCD, Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li K, Palmen J, Howard P, Drenos F, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379:1214-1224.